Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

1983 • 52,849 citations

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

1987 • 11,429 citations

Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer

1989 • 6,734 citations

Cancer statistics, 1997

1997 • 2,045 citations

Enzyme and metabolic inhibitors

1963 • 1,529 citations

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

1996 • 1,393 citations

Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185

1986 • 1,020 citations

erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells

1987 • 1,015 citations

c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer

1994 • 981 citations

Comparison of In Vitro Anticancer-Drug-Screening Data Generated With a Tetrazolium Assay Versus a Protein Assay Against a Diverse Panel of Human Tumor Cell Lines

1990 • 932 citations

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1992 • 855 citations

THE IMPACT OF NATIONAL CANCER ACT

1991 • 809 citations

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

1992 • 769 citations

Breast Cancer

1992 • 695 citations

Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.

1987 • 627 citations

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.

1992 • 466 citations

Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.

1994 • 439 citations

Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies

1985 • 408 citations

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

1997 • 344 citations

Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts

1989 • 316 citations

Breast Cancer

1992 • 303 citations

Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

1991 • 296 citations

Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue.

1988 • 251 citations

Breast Cancer

1992 • 249 citations

Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung.

1990 • 232 citations

Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen.

1986 • 231 citations

A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines.

1991 • 229 citations

Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms.

1996 • 222 citations

Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.

1995 • 220 citations

c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties

1995 • 210 citations

Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment

1995 • 181 citations

Emodin, a Protein Tyrosine Kinase Inhibitor from Polygonum cuspidatum

1992 • 180 citations

Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor.

1992 • 176 citations

Correlation of Intrinsic Chemoresistance of Non-Small-Cell Lung Cancer Cell Lines With HER-2/neu Gene Expression but Not With ras Gene Mutations

1993 • 170 citations

Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin.

1995 • 164 citations

HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.

1997 • 160 citations

Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases.

1989 • 160 citations

Molecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles.

1986 • 158 citations

Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.

1988 • 155 citations

Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma.

1997 • 155 citations

p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.

1994 • 131 citations

Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo.

1988 • 127 citations

Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol

1998 • 124 citations

Monoclonal antibody to a membrane glycoprotein inhibits the acrosome reaction and associated Ca2+ and H+ fluxes of sea urchin sperm

1985 • 119 citations

Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties

1998 • 118 citations

Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy

1995 • 116 citations

Prevention of breast tumour development in vivo by downregulation of the p185neureceptor

1995 • 114 citations

Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin.

1996 • 113 citations

Amplification and expression of the c‐erb B‐2/neu proto‐oncogene in human bladder cancer

1990 • 111 citations

Amplification and rearrangement of c-erb B proto-oncogenes in cancer of human female genital tract.

1989 • 101 citations

Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells.

1991 • 100 citations

Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu.

1995 • 97 citations

Ligand and p185c-neu density govern receptorinteractions and tyrosine kinase activation.

1994 • 92 citations

Enhanced Chemoresistance by Elevation of p185neu Levels in HER-2/neu-Transfected Human Lung Cancer Cells

1995 • 89 citations

The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer

1997 • 82 citations

Oral cancer progression and c-erbB-2/neu proto-oncogene expression

1992 • 79 citations

HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model.

1995 • 70 citations

HER-2/neu-targeting gene therapy-a review

1995 • 69 citations

Prognostic factors and response to therapy in breast cancer.

1993 • 61 citations

Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation.

1989 • 52 citations

Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of p185neu.

1996 • 39 citations

Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185erbB-2 is dependent on the ras signaling pathway

1997 • 39 citations

Low Metastatic Potential of Clone From Murine Colon Adenocarcinoma 26 Increased by Transfection of Activated c-erbB-2 Gene

1990 • 31 citations

Synergism of taxol and gallium nitrate in human breast carcinoma cells: schedule dependency.

1994 • 30 citations

Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer.

1996 • 18 citations

Polymorphic changes of cell phenotype caused by elevated expression of an exogenous NEU proto-oncogene.

1990 • 4 citations

HER2 NEU OVEREXPRESSION COUNTERACTS THE GROWTH EFFECTS OF C-MYC IN BREAST-CANCER CELLS

1994 • 3 citations